###begin article-title 0
###xml 98 99 98 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn2">*</xref>
Assessing Susceptibility to Age-related Macular Degeneration with Proteomic and Genomic Biomarkers*
###end article-title 0
###begin p 1
###xml 199 214 199 214 <email xmlns:xlink="http://www.w3.org/1999/xlink">hagstrs@ccf.org</email>
To whom correspondence may be addressed: Cole Eye Inst. i31, Lerner Research Inst., Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195. Tel.: 216-445-4133; Fax: 216-445-3670; E-mail: hagstrs@ccf.org
###end p 1
###begin p 2
###xml 413 427 413 427 <email xmlns:xlink="http://www.w3.org/1999/xlink">crabbj@ccf.org</email>
Has a license for CEP as an inventor with Frantz Biomarkers, LLC; is a consultant for Alcon Research Ltd. and Allergan, Inc.; and has received funding for this research from Merck & Co. and Johnson and Johnson. To whom correspondence should be addressed: Cole Eye Inst. i31, Lerner Research Inst., Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195. Tel.: 216-445-0425; Fax: 216-445-3670; E-mail: crabbj@ccf.org
###end p 2
###begin p 3
Has a license for CEP as an inventor with Frantz Biomarkers, LLC.
###end p 3
###begin p 4
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice - Final Version Full Access
###end p 4
###begin p 5
 applies to Author Choice Articles
###end p 5
###begin p 6
###xml 887 892 863 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARMS2</italic>
###xml 935 940 911 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTRA1</italic>
###xml 1249 1254 1225 1230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARMS2</italic>
###xml 1259 1264 1235 1240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTRA1</italic>
###xml 767 775 <span type="species:ncbi:9606">patients</span>
Age-related macular degeneration (AMD) is a progressive disease and major cause of severe visual loss. Toward the discovery of tools for early identification of AMD susceptibility, we evaluated the combined predictive capability of proteomic and genomic AMD biomarkers. We quantified plasma carboxyethylpyrrole (CEP) oxidative protein modifications and CEP autoantibodies by ELISA in 916 AMD and 488 control donors. CEP adducts are uniquely generated from oxidation of docosahexaenoate-containing lipids that are abundant in the retina. Mean CEP adduct and autoantibody levels were found to be elevated in AMD plasma by approximately60 and approximately30%, respectively. The odds ratio for both CEP markers elevated was 3-fold greater or more in AMD than in control patients. Genotyping was performed for AMD risk polymorphisms associated with age-related maculopathy susceptibility 2 (ARMS2), high temperature requirement factor A1 (HTRA1), complement factor H, and complement C3, and the risk of AMD was predicted based on genotype alone or in combination with the CEP markers. The AMD risk predicted for those exhibiting elevated CEP markers and risk genotypes was 2-3-fold greater than the risk based on genotype alone. AMD donors carrying the ARMS2 and HTRA1 risk alleles were the most likely to exhibit elevated CEP markers. The results compellingly demonstrate higher mean CEP marker levels in AMD plasma over a broad age range. Receiver operating characteristic curves suggest that CEP markers alone can discriminate between AMD and control plasma donors with approximately76% accuracy and in combination with genomic markers provide up to approximately80% discrimination accuracy. Plasma CEP marker levels were altered slightly by several demographic and health factors that warrant further study. We conclude that CEP plasma biomarkers, particularly in combination with genomic markers, offer a potential early warning system for assessing susceptibility to this blinding, multifactorial disease.
###end p 6
###begin p 7
###xml 38 39 38 39 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn1">1</xref>
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 883 884 883 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 974 975 974 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 1353 1354 1341 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 1492 1493 1480 1481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 681 684 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 688 691 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 878 881 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Age-related macular degeneration (AMD)1 is the most common cause of legal blindness in the elderly in developed countries (1). It is a complex, progressive disease involving multiple genetic and environmental factors that can result in severe visual loss. Early risk factors include the macular deposition of debris (drusen) on Bruch membrane, the extracellular matrix separating the choriocapillaris from the retinal pigment epithelium (RPE). Later stages of "dry" AMD involve the degeneration of photoreceptor and RPE cells resulting in geographic atrophy. In "wet" AMD, abnormal blood vessels grow from the choriocapillaris through Bruch membrane (choroidal neovascularization (CNV)). CNV occurs in 10-15% of AMD cases yet accounts for over 80% of debilitating visual loss in AMD. Anti-vascular endothelial growth factor treatments can effectively inhibit the progression of CNV (1), and antioxidant vitamins and zinc can slow dry AMD progression for select individuals (2). However, there are no universally effective therapies for the prevention of dry AMD or the progression from dry to wet AMD nor are there therapies to repair retinal damage in advanced AMD. The prevalence of advanced AMD in the United States is projected to increase by 50% to approximately3 million by the year 2020 largely because of the rapidly growing elderly population (3). Accordingly early identification of AMD susceptibility and implementation of preventive measures are important therapeutic strategies (1).
###end p 7
###begin p 8
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 389 391 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 461 462 461 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 744 746 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 857 859 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 921 928 921 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 973 975 973 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 1092 1094 1092 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 1096 1098 1096 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 1100 1102 1100 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 1311 1313 1311 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 734 742 <span type="species:ncbi:9606">patients</span>
###xml 968 971 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1136 1140 <span type="species:ncbi:10090">mice</span>
###xml 1169 1174 <span type="species:ncbi:10090">mouse</span>
The molecular mechanisms causing AMD remain unknown, although inflammatory processes have been implicated by the identification of AMD susceptibility genes encoding complement factors (4-10) and the presence of complement proteins in drusen (11-13). Oxidative stress has long been associated with AMD pathology as shown by the finding that smoking significantly increases the risk of AMD (14) and that antioxidant vitamins can selectively slow AMD progression (2). A direct molecular link between oxidative damage and AMD was established by the finding that carboxyethylpyrrole (CEP), an oxidative protein modification generated from docosahexaenoate (DHA)-containing phospholipids, was elevated in Bruch membrane and drusen from AMD patients (11). Subsequently CEP adducts as well as CEP autoantibodies were found to be elevated in plasma from AMD donors (15), and CEP adducts were found to stimulate neovascularization in vivo, suggesting a role in the induction of CNV (16). From such observations, oxidative protein modifications were hypothesized to serve as catalysts of AMD pathology (11, 15, 17). In support of this hypothesis, mice immunized with CEP-adducted mouse albumin develop a dry AMD-like phenotype that includes sub-RPE deposits resembling drusen and RPE lesions mimicking geographic atrophy (18).
###end p 8
###begin p 9
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 281 282 281 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 530 533 530 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFH</italic>
###xml 536 537 536 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 538 539 538 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 553 555 553 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C3</italic>
###xml 557 558 557 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 560 562 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 607 612 607 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARMS2</italic>
###xml 628 637 628 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LOC387715</italic>
###xml 640 642 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 643 645 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 692 697 692 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTRA1</italic>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
Although identified AMD susceptibility genes account for over half of AMD cases (19), many individuals carrying AMD risk genotypes may never develop the disease. Likewise only a fraction of those diagnosed with early AMD progress to advanced stage disease with severe visual loss (2). Toward the discovery of better methods to predict susceptibility to advanced AMD, we quantified CEP adducts and autoantibodies in over 1400 plasma donors and also genotyped many of these donors for AMD risk polymorphisms in complement factor H (CFH) (4-7), complement C3 (9, 10), age-related maculopathy susceptibility 2 (ARMS2; also known as LOC387715) (19-22), and high temperature requirement factor A1 (HTRA1) (23, 24). The results demonstrate that combined CEP proteomic and genomic biomarker measurements are more effective in assessing AMD risk than either method alone.
###end p 9
###begin title 10
EXPERIMENTAL PROCEDURES
###end title 10
###begin title 11
Case-Control Study Design-
###end title 11
###begin p 12
###xml 784 785 784 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 345 353 <span type="species:ncbi:9606">patients</span>
###xml 481 486 <span type="species:ncbi:9606">human</span>
###xml 685 693 <span type="species:ncbi:9606">patients</span>
###xml 811 819 <span type="species:ncbi:9606">patients</span>
###xml 1079 1087 <span type="species:ncbi:9606">patients</span>
###xml 1334 1342 <span type="species:ncbi:9606">patients</span>
###xml 1393 1401 <span type="species:ncbi:9606">patients</span>
###xml 1442 1445 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Clinically documented AMD and control blood donors were recruited prospectively between 2003 and 2008 from the Cole Eye Institute, Cleveland Clinic Foundation, and the Eye Clinic, Louis Stokes Cleveland Veterans Affairs Medical Center with the approval of each Institutional Review Board and according to Declaration of Helsinki principles. All patients received a comprehensive eye examination by a clinician in the Clinical Study Group and provided written informed consent. All human identifiers were removed from blood specimens and were encoded by the Clinical Study Group to protect donor confidentiality. AMD disease progression was categorized based on fundus examination, and patients were included in the study from Age-Related Eye Disease Study AMD categories 2, 3, and 4 (2). Briefly AMD category 2 patients exhibited early stage disease with multiple small drusen, single or nonextensive intermediate drusen (63-124 mum), RPE pigmentary abnormalities, or any combination of these in one or both eyes and visual acuity of 20/30 or better in both eyes. AMD category 3 patients exhibited midstage disease with at least one eye having visual acuity of 20/30 or better and one large drusen (125 mum), extensive intermediate drusen, or geographic atrophy that did not involve the macula or any combination of these. Category 3 patients lacked advanced AMD in either eye. AMD category 4 patients exhibited advanced AMD with substantial CNV or geographic atrophy involving the macula in one or both eyes. Control donors lacked macular drusen and exhibited no clinical evidence of any retinal disorder. Plasma and DNA pellets were prepared from blood specimens and stored frozen until analysis as described below.
###end p 12
###begin title 13
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Plasma Preparation-
###end title 13
###begin p 14
###xml 63 64 61 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 285 287 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
Nonfasting blood specimens were collected in BD Vacutainer(R) K2EDTA tubes, and plasma was prepared within 6 h and aliquoted to vials containing the antioxidant butylated hydroxytoluene (1 mg/ml plasma) and a protease inhibitor mixture (Sigma product number P 8340; 10 mul/ml plasma) (15). The plasma was flushed with argon, quench frozen in liquid nitrogen immediately, and stored at -80 degreesC. Storage time at -80 degreesC prior to analysis ranged from 1 to 10 months and averaged 4 months over the 5-year study period. All samples were frozen and thawed only once.
###end p 14
###begin title 15
ELISA-
###end title 15
###begin p 16
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 544 546 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 548 550 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 44 50 <span type="species:ncbi:9986">rabbit</span>
###xml 229 234 <span type="species:ncbi:9606">human</span>
###xml 464 469 <span type="species:ncbi:9606">human</span>
CEP adducts were detected with IgG purified rabbit anti-CEP polyclonal antibody and quantified as described previously using a competitive ELISA using CEP-modified BSA (CEP-BSA) as coating agent and known amounts of CEP-modified human serum albumin as reference protein (ELISA method B in Ref. 15). CEP autoantibody titers were measured by direct ELISA using CEP-BSA as coating antigen as described previously (ELISA method C in Ref. 15). CEP-BSA and CEP-modified human serum albumin were synthesized and characterized as described previously (15, 25).
###end p 16
###begin title 17
Western Analysis-
###end title 17
###begin p 18
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
Western analysis of plasma proteins from AMD and normal donors was performed as described previously (11). CEP immunoreactivity was detected by chemiluminescence and quantified by densitometry using a Bio-Rad GS-710 instrument.
###end p 18
###begin title 19
Genotyping-
###end title 19
###begin p 20
###xml 96 101 96 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTRA1</italic>
###xml 139 141 139 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C3</italic>
###xml 189 192 189 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFH</italic>
###xml 311 316 311 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARMS2</italic>
###xml 318 327 318 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LOC387715</italic>
DNA was isolated from blood using standard procedures. AMD risk polymorphisms were genotyped in HTRA1 (rs11200638 in the promoter region), C3 (rs2230199 encoding an R102G interchange), and CFH (rs1061170 encoding a Y402H interchange) by restriction analysis with EagI, HhaI, and Hsp92II, respectively. Those in ARMS2 (LOC387715 rs10490924 encoding an A69S interchange) were determined by direct DNA sequence analysis using an Applied Biosystems model 3130 XL instrument.
###end p 20
###begin title 21
Statistical Analysis-
###end title 21
###begin p 22
###xml 322 323 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 799 800 799 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1436 1437 1436 1437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1644 1645 1644 1645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 281 289 <span type="species:ncbi:9606">patients</span>
Continuous measures were summarized using means, standard deviations, medians, and interquartile ranges, whereas categorical factors were described using frequencies and percentages. Differences in plasma CEP adduct concentration and CEP autoantibody titer between control and AMD patients were evaluated using two-sample t tests in Minitab Release 15 (Minitab Inc.). To evaluate a relationship between CEP adducts and autoantibody titer with AMD susceptibility, a logistic regression model was fit with both variables as predictors of AMD using Proc Logistic in SAS 9.1 (SAS Institute Inc., Cary, NC). C-statistics measured the ability of the model to discriminate between AMD and controls, whereas odds ratios (ORs) showed the change in risk of AMD based on the predictors. ORs, c-statistics, and p values were determined based on log-transformed CEP marker concentrations. Validation of c-statistics was performed using 2000 bootstrap (random) resamplings to calculate empirical 95% confidence intervals (CI) and by performing 10-fold cross-validation. Sensitivity and specificity were calculated to maximize the sum of the two values using receiver operating characteristic (ROC) curves constructed with SAS 9.1 from the output of logistic regression analysis fit with either CEP adduct concentrations plus autoantibody titers, homozygous risk genotype, or the combination of the CEP markers and the risk genotype. C-statistics and p values comparing ROC curves were determined with SAS 9.1. For association analyses of combined effects of plasma CEP adducts and autoantibody titer with AMD risk genotypes, ORs with 95% CI and Fisher exact p values were calculated with SAS 9.1 software. Pearson's correlation analysis in Minitab Release 15 was used to compare CEP marker concentrations with plasma donor age.
###end p 22
###begin title 23
RESULTS
###end title 23
###begin title 24
Elevated CEP Adducts and Autoantibodies in AMD Plasma-
###end title 24
###begin p 25
###xml 211 217 211 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 219 220 219 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 225 226 225 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 232 239 232 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table I</xref>
###xml 466 467 442 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 718 720 670 672 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 793 794 733 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 928 934 868 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2</xref>
###xml 1135 1142 1075 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table I</xref>
###xml 358 366 <span type="species:ncbi:9606">patients</span>
Plasma samples from a total of 488 control subjects and 916 AMD subjects, including 177 with early stage dry AMD, 130 with midstage dry AMD, and 609 with advanced stage AMD, were analyzed by ELISA. The results (Fig. 1, A and B, and Table I) demonstrate higher mean levels of CEP adducts (approximately1.6x) and autoantibody titers (approximately1.3x) in AMD patients relative to control plasma. Comparison of log-transformed values confirmed the results and yielded p values <0.0001. Data from duplicate adduct and triplicate autoantibody measurements exhibited average intra-assay variability of approximately4% for adducts and approximately8% for autoantibodies. Interassay, day-to-day variability, as measured by IC50, averaged approximately25%. Western analysis of AMD and control plasma (n = 10 each) demonstrated that CEP adducts are associated with proteins and also supported higher levels of the adducts in AMD plasma (Fig. 2). Plasma from all categories of AMD progression, including early stage AMD, exhibited elevated mean levels of CEP adducts and autoantibodies with no significant difference between disease categories (Table I).
###end p 25
###begin p 26
###xml 51 57 51 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1</xref>
###xml 59 60 59 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 65 66 65 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 471 479 471 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table II</xref>
###xml 633 641 633 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table II</xref>
###xml 1074 1081 1074 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table I</xref>
###xml 147 155 <span type="species:ncbi:9606">patients</span>
###xml 325 333 <span type="species:ncbi:9606">patients</span>
###xml 388 394 <span type="species:ncbi:9606">person</span>
###xml 623 631 <span type="species:ncbi:9606">patients</span>
###xml 937 945 <span type="species:ncbi:9606">patients</span>
###xml 1012 1020 <span type="species:ncbi:9606">patients</span>
Correlation of CEP adduct and autoantibody levels (Fig. 1, C and D) revealed both markers to be elevated above median control levels in 56% of AMD patients (515 of 916) compared with only 29% of control donors (141 of 488). Logistic regression modeling of all control and AMD data yielded a c-statistic equal to 0.76 for AMD patients, supporting a 76% likelihood that a randomly selected person with both CEP variables elevated will be an AMD case rather than a control (Table II). Little difference in c-statistics (0.73-0.77) was observed from logistic regression modeling of the data from early, mid-, or late stage AMD patients (Table II), and bootstrap resampling and 10-fold cross-validation supported all c-statistics and 95% CIs. The predicted risk of AMD was measured by OR for donors with both CEP markers elevated relative to the median of the control plasma. The ORs for all (3.17), for midstage (3.25), and for advanced AMD patients (2.91) were found to be similar, whereas that for early stage AMD patients was slightly higher (4.24) but with a larger 95% CI (Table I).
###end p 26
###begin title 27
AMD Risk Based on CEP Markers and Genotype-
###end title 27
###begin p 28
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARMS2</italic>
###xml 61 66 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTRA1</italic>
###xml 68 71 68 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFH</italic>
###xml 77 79 77 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C3</italic>
###xml 106 107 106 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 128 129 128 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 259 260 259 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 253 260 253 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 517 518 517 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 511 518 511 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 569 574 569 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARMS2</italic>
###xml 857 862 821 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTRA1</italic>
###xml 864 867 828 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFH</italic>
###xml 873 875 837 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C3</italic>
###xml 1045 1054 1009 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t3">Table III</xref>
###xml 1069 1077 1033 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t4">Table IV</xref>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
Genotyping for AMD risk polymorphisms associated with ARMS2, HTRA1, CFH, and C3 was performed on control (n = 233-404) and AMD (n = 708-788) patients, and the predicted risk of AMD was estimated by OR for the heterozygous and homozygous risk genotypes. Fig. 3A shows that the ORs based on homozygous genotype alone were greater than those based on CEP markers alone for advanced AMD as well as for all AMD donors. Combining CEP measurements and genotype resulted in higher ORs for AMD than from genotype alone (Fig. 3A). For example, for individuals homozygous for the ARMS2 risk genotype, elevated CEP levels increased the OR for AMD from 7.32 to 20.88 (approximately2.8-fold) for all AMD cases and from 10.54 to 27.74 (approximately2.6-fold) for advanced AMD cases. Similarly the OR for AMD based on genotype alone increased approximately2-3-fold for the HTRA1, CFH, and C3 risk alleles when combined with elevated CEP levels. Genotype frequencies and ORs with 95% CI for homozygous risk, non-risk, and heterozygous genotypes are presented in Table III (all AMD) and Table IV (advanced AMD). Notably combining CEP measurements with either heterozygous or homozygous genotype resulted in higher ORs for AMD.
###end p 28
###begin p 29
###xml 185 192 185 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t5">Table V</xref>
Sensitivity and specificity measures were determined from ROC curves for all AMD cases and controls for the CEP markers alone, the four genomic markers alone, and the combined markers (Table V). Calculated to maximize the sum of the two values, sensitivity (approximately73%) was greater for the CEP markers than for any of the genomic markers alone (31-60%), whereas specificity was greater for the genomic markers (77-94%). The combined markers exhibited 63-75% sensitivity and 67-81% specificity. The areas under the ROC curves (c-statistics) were verified by bootstrap sampling and by 10-fold cross-validation and were greater for the combined markers (0.76-0.80) and CEP alone (0.76) than for the genomic markers alone (0.62-0.69).
###end p 29
###begin p 30
###xml 213 214 213 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 207 214 207 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 379 384 367 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARMS2</italic>
###xml 389 394 377 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTRA1</italic>
###xml 396 397 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 420 423 406 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFH</italic>
###xml 428 430 414 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C3</italic>
###xml 454 455 440 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 520 528 506 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t6">Table VI</xref>
To probe for possible associations between CEP marker levels and AMD risk genotypes, we evaluated ORs for elevated CEP markers in the advanced AMD cohort and in the entire AMD study population. The results (Fig. 3B) show an approximately2-fold significant increase in the OR for elevated CEP markers over the non-risk genotype for AMD donors carrying homozygous risk alleles for ARMS2 and HTRA1 (p </= 0.03) but not for CFH and C3. Genotype frequencies, p values, and ORs with 95% CI for these analyses are presented in Table VI.
###end p 30
###begin title 31
The Influence of Demographic and Health Factors on Plasma CEP Markers-
###end title 31
###begin p 32
###xml 101 110 101 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t7">Table VII</xref>
###xml 165 171 165 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4</xref>
###xml 483 489 483 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4</xref>
###xml 257 265 <span type="species:ncbi:9606">patients</span>
###xml 390 398 <span type="species:ncbi:9606">patients</span>
Study population characteristics, including age, gender, race, and health history, are summarized in Table VII. Comparison of plasma CEP marker levels by donor age (Fig. 4) revealed that CEP adduct concentrations are relatively stable with age and that AMD patients had significantly higher mean levels than controls at all ages. Mean CEP autoantibody titer remained stable with age in AMD patients and was higher than in controls but increased gradually with age in control donors (Fig. 4). Comparison of log-transformed CEP marker concentrations (not shown) confirmed these results.
###end p 32
###begin p 33
###xml 176 182 176 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5</xref>
###xml 999 1005 999 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5</xref>
###xml 462 470 <span type="species:ncbi:9606">patients</span>
Plasma CEP marker concentrations were also compared by gender, race, and health history, including smoking, hypertension, hyperlipidemia, diabetes, and cardiovascular disease (Fig. 5). For each comparison, significant differences in CEP adduct and autoantibody concentrations were observed between AMD and control donors. For several of the comparisons, small but significant differences were also detected within the AMD or control cohorts. Specifically in AMD patients, mean CEP adduct levels were higher in Caucasians relative to African-Americans, in females relative to males, and in donors exhibiting hypertension and hyperlipidemia. Within the control cohorts, no significant differences were detected in mean amounts of CEP adducts. However, mean CEP autoantibody titers were slightly higher in control males, control smokers, and controls with diabetes or cardiovascular disease. AMD donors with hypertension and hyperlipidemia also exhibited slightly higher amounts of CEP autoantibodies (Fig. 5).
###end p 33
###begin title 34
DISCUSSION
###end title 34
###begin p 35
###xml 79 83 79 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g.</italic>
###xml 108 109 102 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 224 226 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 228 230 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 388 390 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 697 699 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 701 703 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 949 951 943 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 953 955 947 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 998 999 992 993 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1061 1063 1055 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 324 329 <span type="species:ncbi:9606">human</span>
###xml 934 937 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1092 1100 <span type="species:ncbi:9606">patients</span>
CEP modifications are generated by covalent adduction of primary amino groups (e.g. protein epsilon-lysyl NH2) with 4-hydroxy-7-oxohept-5-enoic acid, an oxidation fragment derived uniquely from DHA-containing phospholipids (15, 25). DHA is the most oxidizable of all fatty acids, and although rare, its highest abundance in human tissues is found in retinal photoreceptor outer segments (26). The high oxygen tension in the retina coupled with light provides a permissive environment for the generation of oxidative post-translational modifications. For example, rodents exposed to intense light accumulate elevated CEP adducts in the retina and elevated CEP adducts and autoantibodies in plasma (27, 28). Of course other oxidative protein modifications accumulate in the eye with age and possibly contribute to AMD pathogenesis. Such modifications include advanced glycation end products in the choriocapillaris, Bruch membrane, and CNV membranes (29, 30) and nitrotyrosine and iso[4]levuglandin E2 adducts (as well as CEP adducts) in RPE lipofuscin granules (31). Why ocular tissues in AMD patients are more susceptible to oxidative damage than normal eye tissue remains to be determined, but oxidative markers formed from retina-rich components like DHA lipids offer a potential early warning system for predicting AMD susceptibility.
###end p 35
###begin p 36
###xml 65 66 65 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 268 269 256 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 378 380 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 564 568 540 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g.</italic>
###xml 953 957 929 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e.</italic>
###xml 1598 1600 1574 1576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 2104 2106 2080 2082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 368 376 <span type="species:ncbi:9606">patients</span>
###xml 1043 1051 <span type="species:ncbi:9606">patients</span>
We characterized plasma CEP markers in a large study population (n = 1404) and confirmed that mean levels of CEP adducts and autoantibodies are elevated in AMD plasma. The present study found mean CEP adduct concentrations to be approximately60% higher in AMD plasma (p < 0.0001), which is similar to the approximately50% mean elevation previously reported for 19 AMD patients (15). Western analysis also supported higher levels of CEP adducts in AMD plasma and clearly associated adducts with proteins. These data do not exclude CEP adduction of small molecules, e.g. phosphatidylethanolamines, which also likely occurs. Significant variability in CEP adduct concentrations was observed among both normal and AMD donors as reflected by differences in mean and median levels; however, mean plasma levels changed little with age for either AMD or normal donors. Notably mean CEP adduct concentrations were already elevated in the youngest AMD age group (i.e. 51-60 years) and in plasma from those with early stage dry AMD. Interestingly in AMD patients, significantly higher CEP adduct levels were observed in females, consistent with the higher incidence of AMD in females, and in hyperlipidemic individuals, consistent with the lipid source of these adducts. African-Americans with AMD exhibited significantly lower CEP adduct levels than Caucasians, consistent with the lower incidence of AMD in African-Americans and consistent with a greater resistance to oxidative damage perhaps because of the higher levels of ocular melanin in darkly pigmented races and the antioxidant effects of melanin (32). Surprisingly smoking had little impact on plasma CEP adduct levels within either the control or AMD cohorts presumably because of relatively low amounts of DHA in the pulmonary system. The present analyses also detected no confounding influences on plasma CEP adduct concentrations from diabetes and cardiovascular disease, although AMD donors with hypertension exhibited slightly higher levels. Epidemiological studies have inconsistently associated hypertension and cardiovascular disease with AMD (33).
###end p 36
###begin p 37
###xml 91 92 79 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 345 349 333 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e.</italic>
This study found mean CEP autoantibody titers to be approximately30% higher in AMD plasma (p < 0.0001) and to remain relatively constant with age in AMD plasma but to gradually increase with age in control plasma. It is important to note that the mean CEP autoantibody titers in AMD plasma were above mean control levels over a broad age range (i.e. 51-80 years) and for those with early stage dry AMD. In contrast to CEP adducts, mean CEP autoantibody titers were elevated slightly with statistical significance in control males, control smokers, and controls with diabetes or cardiovascular disease. These differences warrant consideration as possible factors that might impact CEP marker predictions of AMD, although their biochemical basis and clinical relevance remain to be determined. In AMD cohorts, mean CEP autoantibody titer exhibited no detectable differences with regard to race, gender, smoking, diabetes, and cardiovascular disease but were elevated in those with hypertension or hyperlipidemia.
###end p 37
###begin p 38
###xml 61 67 61 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 387 389 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 274 282 <span type="species:ncbi:9606">patients</span>
Mean CEP adduct and autoantibody levels were elevated in AMD versus control plasma donors, but the individual values for both markers were spread across a broad range and exhibited standard deviations up to 67% of the mean. The 30% higher mean CEP autoantibody titer in AMD patients observed here differed from the 2.3-fold elevation previously estimated from 19 AMD and control donors (15). We credit this difference in part to the greater variability of the previous antibody values and the smaller sample size of the previous study. However, although genetic diversity certainly contributed to the range of determined CEP marker values, interassay variability over the 5-year study period also contributed to variability. For broad clinical usefulness as biomarkers, it will be important to further standardize the CEP marker assay conditions. For example, a fasting blood specimen that is assayed without freezing or significant storage time, as in clinical lipid analyses for cholesterol, could significantly decrease variability. Nevertheless the present results compellingly demonstrate higher CEP marker levels in AMD plasma, and the areas under the ROC curves (c-statistics) suggest that alone these markers can discriminate between AMD and control plasma donors with approximately76% accuracy.
###end p 38
###begin p 39
###xml 181 186 181 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARMS2</italic>
###xml 188 193 188 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTRA1</italic>
###xml 198 201 198 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFH</italic>
###xml 317 319 317 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C3</italic>
###xml 771 776 759 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARMS2</italic>
###xml 778 783 766 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTRA1</italic>
###xml 785 788 773 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFH</italic>
###xml 794 796 782 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C3</italic>
###xml 1048 1053 1036 1041 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARMS2</italic>
###xml 1057 1062 1045 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTRA1</italic>
###xml 1117 1120 1105 1108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFH</italic>
###xml 1124 1126 1112 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C3</italic>
###xml 1395 1400 1383 1388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARMS2</italic>
###xml 1454 1456 1442 1444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 1463 1468 1451 1456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTRA1</italic>
###xml 1527 1529 1515 1517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 1531 1533 1519 1521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
About a 3-fold higher risk of AMD was predicted for plasma donors with both CEP adducts and autoantibodies elevated above median control levels. Although the risk of AMD due to the ARMS2, HTRA1, or CFH homozygous risk polymorphisms was about 2-fold higher than that due to elevated CEP markers alone, that due to the C3 risk allele approximated that associated with elevated CEP. More importantly, the risk for AMD predicted for individuals carrying any of the four characterized risk genotypes and exhibiting elevated CEP marker concentrations was approximately2-3-fold greater than that predicted by genotype alone. Combining the CEP and genomic markers significantly improved the discrimination accuracy (c-statistics) of all the genomic markers. The frequency of the ARMS2, HTRA1, CFH, and C3 homozygous AMD risk alleles in this study population was in reasonable agreement with the range of values previously reported as were the determined odds ratios for AMD risk based on genotype alone. Within the AMD population, individuals carrying the ARMS2 or HTRA1 homozygous risk genotypes, but not those carrying the CFH or C3 risk genotypes, were approximately twice as likely to exhibit elevated CEP markers than those carrying the homozygous non-risk alleles. The significance of these associations is not known but may be related to the sensitivity of the gene products to oxidative stress: ARMS2 encodes a mitochondrial protein of unknown function (19), and HTRA1 encodes a heat shock serine protease activated by stress (23, 24).
###end p 39
###begin p 40
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 363 365 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 418 423 418 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARMS2</italic>
###xml 425 427 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 433 436 433 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFH</italic>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
Systemic biomarkers of inflammation have been associated with AMD, but published reports are inconsistent. For example, elevated levels of C-reactive protein, homocysteine, and interleukin 6 have been implicated in the development of AMD (34-37), but several other case-control studies have found no association with AMD for these and other inflammatory markers (38-40). Studies evaluating the combined effects of the ARMS2 (39) and CFH (41) risk genotypes and inflammatory markers on increased risk for AMD have also been reported, but no studies have yet addressed the sensitivity and specificity of systemic markers for AMD. Sample preparation, specimen storage, and assay methods varied in these studies and likely contributed to the inconsistency of the reports. Although systemic biomarkers of inflammation warrant consideration as tools for monitoring this multifactorial disease, CEP biomarkers offer potentially greater sensitivity and specificity for AMD because of their unique derivation from abundant components of the outer retina namely DHA phospholipids.
###end p 40
###begin p 41
###xml 698 700 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 307 315 <span type="species:ncbi:9606">patients</span>
###xml 584 589 <span type="species:ncbi:10090">mouse</span>
Taken together, this study supports the potential utility of CEP proteomic biomarkers for predicting AMD susceptibility, particularly in combination with genomic markers. The statistical analyses suggest that plasma CEP marker levels in combination with genomic markers discriminate between AMD and control patients with up to approximately80% accuracy. Standardization of the CEP marker assay could further improve discrimination accuracy. The current results warrant additional prospective and longitudinal investigation of clinical applications. Notably a recent study showed in a mouse model of dry AMD that CEP autoantibody titer increases in direct proportion to the severity of RPE lesions (18). This observation suggests that CEP biomarkers may have utility in monitoring the efficacy of therapeutics that prevent or limit the progression of dry AMD.
###end p 41
###begin p 42
###xml 117 124 <span type="species:ncbi:9606">patient</span>
###xml 732 740 <span type="species:ncbi:9606">patients</span>
The Clinical Genomic and Proteomic AMD Study Group was composed of the following clinicians who performed ophthalmic patient examinations: Dr. David Barnhart, Dr. William J. Dupps, Dr. Froncie A. Gutman, Dr. Peter K. Kaiser, Dr. Hilel Lewis, Dr. Richard E. Gans, Dr. Bennie H. Jeng, Dr. Gregory S. Kosmorsky, Dr. Ronald R. Krueger, Dr. Ann Laurenzi, Dr. Roger H. S. Langston, Dr. Edward J. Rockwood, Dr. William E. Sax, Dr. Andrew P. Schachat, Dr. Jonathan E. Sears, Dr. Rishi Singh, Dr. Scott D. Smith, Dr. Mindy Toabe, Dr. Elias I. Traboulsi, Dr. Nadia Waheed, Dr. Steven E. Wilson, and Dr. Stacia S. Yaniglos. The study group also included the following individuals who obtained written informed consent and blood specimens from patients: Dr. Elisa Bala, Dr. Sonya Bamba, Sue Crowe, Patrice Nerone, Tiffany Ruez, and Ellen Simpson. We thank Drs. Joe G. Hollyfield and Bela Anand-Apte for valuable discussions.
###end p 42
###begin title 43
REFERENCES
###end title 43
###begin p 44
Published, MCP Papers in Press, February 6, 2009, DOI 10.1074/mcp.M800453-MCP200
###end p 44
###begin p 45
###xml 163 166 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
The abbreviations used are: AMD, age-related macular degeneration; CEP, carboxyethylpyrrole; CFH, complement factor H; C3, complement C3; CI, confidence interval; CNV, choroidal neovascularization; DHA, docosahexaenoic acid; HTRA1, high temperature requirement factor A1; ARMS2, age-related maculopathy susceptibility 2 (also known as LOC387715); OR, odds ratio; ROC, receiver operating characteristic; RPE, retinal pigment epithelium.
###end p 45
###begin p 46
###xml 49 78 49 78 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">National Institutes of Health</grant-sponsor>
###xml 86 94 86 94 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">EY015638</grant-num>
###xml 96 104 96 104 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">EY014239</grant-num>
###xml 106 113 106 113 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">GM21249</grant-num>
###xml 119 127 119 127 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">EY016072</grant-num>
This work was supported, in whole or in part, by National Institutes of Health Grants EY015638, EY014239, GM21249, and EY016072. This work was also supported by Grant BRTT 05-29 from the State of Ohio, a Foundation Fighting Blindness Center grant, a Research to Prevent Blindness (RPB) center grant, a RPB senior investigator award (to J. W. C.), a Steinbach award (to J. W. C.), the Veterans Affairs Medical Research Service, and the Cleveland Clinic Foundation.
###end p 46
###begin p 47
###xml 0 58 0 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CEP adducts and autoantibodies are elevated in AMD plasma.</bold>
###xml 86 87 86 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 114 115 114 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 151 152 151 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 169 170 169 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 267 269 255 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Q1</italic>
###xml 271 273 259 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Q3</italic>
###xml 316 317 302 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 336 337 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 425 432 411 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table I</xref>
###xml 553 554 539 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 565 566 551 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 581 591 567 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">horizontal</italic>
###xml 596 617 582 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vertical dashed lines</italic>
###xml 760 781 746 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upper right quadrants</italic>
###xml 785 786 771 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 791 792 777 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 729 737 <span type="species:ncbi:9606">patients</span>
CEP adducts and autoantibodies are elevated in AMD plasma. CEP adduct concentrations (A) and autoantibody titers (B) quantified by ELISA from control (n = 488) and AMD (n = 916) plasma donors are shown with median (triangle up) results +/- first and third quartiles (Q1, Q3) and mean (o) results +/- S.D. indicated. p values (two-sided t test) were determined from log-transformed concentrations. These data are presented in Table I by category of AMD progression. Correlation between CEP adduct levels and autoantibody titers is shown for the control (C) and AMD (D) cohorts with horizontal and vertical dashed lines indicating median control values. Significantly more donors with both CEP markers elevated are apparent in AMD patients than in the controls (upper right quadrants in C and D).
###end p 47
###begin p 48
###xml 0 59 0 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Western analysis of AMD and control plasma for CEP adducts.</bold>
###xml 380 381 355 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 461 462 424 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 682 683 645 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 714 715 677 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 723 733 686 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Error bars</italic>
###xml 794 795 757 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1049 1050 1012 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1060 1061 1023 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M</italic>
###xml 60 65 <span type="species:ncbi:9606">Human</span>
###xml 198 203 <span type="species:ncbi:10090">mouse</span>
###xml 1008 1011 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Western analysis of AMD and control plasma for CEP adducts. Human AMD and control donor plasma samples were subjected to SDS-PAGE (approximately15 mug/lane), electroblotted to PVDF, and probed with mouse monoclonal anti-CEP antibody. CEP adducts (immunoreactivity) are shown to be associated with high molecular mass components (>approximately40 kDa) after 1-min autoradiography (A) and also with components of approximately25 kDa after 60-min autoradiography (B). Additional components become apparent with longer autoradiography time. Densitometric quantification of CEP immunoreactivity in the indicated bands supports more CEP-adducted proteins in AMD than normal donor plasma (p values are from the two-sided t test). Error bars reflect standard deviation. The Coomassie Blue-stained gel (C) shows that approximately equal amounts of protein were applied per lane for the Western analysis. The age and sex of each donor are listed, and for AMD samples, the asterisk (*) and # symbols denote donors with CNV or geographic atrophy, respectively. F, female; M, male.
###end p 48
###begin p 49
###xml 0 47 0 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink">AMD risk predicted by CEP markers and genotype.</bold>
###xml 47 48 47 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 167 172 167 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARMS2</italic>
###xml 174 179 174 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTRA1</italic>
###xml 181 184 181 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFH</italic>
###xml 189 191 189 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C3</italic>
###xml 246 247 246 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 267 268 267 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 280 281 280 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 546 547 546 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 559 560 559 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 592 597 592 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARMS2</italic>
###xml 602 607 602 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HTRA1</italic>
###xml 620 623 620 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFH</italic>
###xml 628 630 628 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C3</italic>
###xml 683 684 683 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 709 719 709 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t3">Tables III</xref>
###xml 721 723 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t4">IV</xref>
###xml 729 731 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t6">VI</xref>
###xml 749 750 749 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 270 278 <span type="species:ncbi:9606">patients</span>
###xml 415 423 <span type="species:ncbi:9606">patients</span>
AMD risk predicted by CEP markers and genotype.A, odds ratios for AMD risk based on elevated CEP markers only, genotype only (specific for the homozygous risk alleles ARMS2, HTRA1, CFH and C3), and the joint effect of both are shown for all AMD (a) and advanced AMD (b) patients. B, odds ratios for both CEP markers to be elevated in AMD risk and non-risk homozygous genotypes are shown for all AMD or advanced AMD patients. Differences in CEP marker concentrations between homozygous risk and non-risk donors were statistically significant (**, p < 0.01; *, p < 0.05; Fisher exact test) for ARMS2 and HTRA1 but not for CFH and C3. Sample size, gene frequencies, OR with 95% CI, and p values are presented in Tables III, IV, and VI. OR, 95% CI, and p values were determined with log-transformed CEP marker concentrations.
###end p 49
###begin p 50
###xml 0 51 0 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Plasma CEP adducts and autoantibodies by donor age.</bold>
###xml 71 72 71 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 103 104 103 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 219 247 209 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">horizontal color-coded lines</italic>
###xml 252 253 242 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 444 445 434 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 476 477 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 563 564 551 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">y</italic>
###xml 567 568 555 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 589 590 577 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 606 607 594 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 632 633 620 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 649 650 637 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 676 677 664 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 693 694 681 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 722 723 710 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 738 739 726 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 847 856 835 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Asterisks</italic>
###xml 865 866 853 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 891 892 879 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 904 905 892 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 919 920 907 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 936 937 924 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 947 957 935 945 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Error bars</italic>
Plasma CEP adducts and autoantibodies by donor age. Plasma CEP adduct (A) and CEP autoantibody levels (C) in the AMD (triangle up) and control (*) cohorts are shown plotted by donor age. Pearson's correlation analysis (horizontal color-coded lines and p value from log-transformed data) revealed little change in mean CEP marker concentrations with age except for a gradual increase in CEP autoantibody titer in the control cohort. CEP adduct (B) and CEP autoantibody levels (D) in AMD and control donors are plotted by age group, including controls </=50 years (y) (n = 98), 51-60 years (n = 138 control, n = 26 AMD), 61-70 years (n = 153 control, n = 123 AMD), 71-80 years (n = 154 control, n = 389 AMD), and >80 years (n = 43 control, n = 378 AMD). -Fold difference in CEP marker concentrations is indicated between the control and AMD groups. Asterisks reflect p values from a two-sided t test (***, p < 0.001; **, p < 0.01; and *, p < 0.05). Error bars reflect standard deviation.
###end p 50
###begin p 51
###xml 0 64 0 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Plasma CEP markers stratified by demographic and health factors.</bold>
###xml 340 349 340 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">asterisks</italic>
###xml 358 359 358 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 384 385 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 442 443 442 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 457 458 457 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 474 475 474 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 485 489 485 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cauc</italic>
###xml 502 508 502 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Afr Am</italic>
###xml 528 529 528 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 539 540 539 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M</italic>
###xml 548 549 548 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 560 562 560 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NS</italic>
###xml 577 578 577 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w</italic>
###xml 586 589 586 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">w/o</italic>
###xml 600 610 600 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Error bars</italic>
Plasma CEP markers stratified by demographic and health factors. Plasma CEP adduct and CEP autoantibody levels in the AMD and control study populations are plotted based on donor status with regard to race, gender, smoking status, hypertension, hyperlipidemia, diabetes, and cardiovascular diseases. Sample size per group is indicated, and asterisks reflect p values from a two-sided t test of log-transformed CEP marker concentrations (***, p < 0.001; **, p < 0.01; and *, p < 0.05). Cauc, Caucasian; Afr Am, African-American; F, female; M, male; S, smoking; NS, non-smoking; w, with; w/o, without. Error bars reflect standard deviation.
###end p 51
###begin p 52
###xml 0 37 0 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CEP markers in AMD and control plasma</italic>
CEP markers in AMD and control plasma
###end p 52
###begin p 53
###xml 262 263 258 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 401 402 397 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 430 431 426 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
CEP adduct concentration and autoantibody titer were determined by ELISA. Odds ratios reflect the AMD risk for donors exhibiting elevated levels of both CEP markers relative to median control levels (>/=19 pmol/ml CEP adducts and >/=1.3 CEP autoantibody titer). p values were determined using the Fisher exact test. AMD categories are based on the Age-Related Eye Disease Study classification system (2). Odds ratios, 95% CI, and p values are based on log-transformed CEP marker concentrations. Ab, antibody.
###end p 53
###begin p 54
###xml 0 28 0 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-statistics for CEP markers</italic>
c-statistics for CEP markers
###end p 54
###begin p 55
The c-statistic and 95% CI were determined by a logistic regression model fitted with log-transformed CEP adduct concentration and autoantibody titer as independent variables and were validated by bootstrap resampling and 10-fold cross-validation.
###end p 55
###begin p 56
###xml 0 54 0 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AMD risk for all AMD based on genotype and CEP markers</italic>
AMD risk for all AMD based on genotype and CEP markers
###end p 56
###begin p 57
Odds ratios were determined for all AMD risk based on genotype alone or based on the joint effect of genotype plus elevated levels of both CEP markers relative to median control levels (>/=19 pmol/ml CEP adducts and >/=1.3 CEP autoantibody titer). Odds ratios and 95% CI involving CEP markers are based on log-transformed concentrations.
###end p 57
###begin p 58
###xml 0 59 0 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AMD risk for advanced AMD based on genotype and CEP markers</italic>
AMD risk for advanced AMD based on genotype and CEP markers
###end p 58
###begin p 59
Odds ratios were determined for advanced AMD risk based on genotype alone or based on the joint effect of genotype plus elevated levels of both CEP markers relative to median control levels (>/=19 pmol/ml CEP adducts and >/=1.3 CEP autoantibody titer). Odds ratios and 95% CI involving CEP markers are based on log-transformed concentrations.
###end p 59
###begin p 60
###xml 0 62 0 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sensitivity and specificity of CEP markers and genomic markers</italic>
Sensitivity and specificity of CEP markers and genomic markers
###end p 60
###begin p 61
###xml 346 347 346 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Sensitivity and specificity were determined from ROC curves to maximize the sum of the two values and constructed from the output of logistic regression analysis fit with either CEP adduct concentrations plus autoantibody titers, homozygous risk genotype, or the combination of the CEP biomarkers and the risk genotype. c-statistics, 95% CI, and p values derived from single and joint markers were determined with SAS 9.1 based on log-transformed CEP marker concentrations. Verification of c-statistics and 95% CI was performed by bootstrap resampling and 10-fold cross-validation. The c-statistic is a measure of the area under the ROC curve and the accuracy of the markers to discriminate between AMD cases and controls with 1.0 equivalent to 100% accuracy and 0.5 equal to no discrimination. Combining the CEP and genomic markers significantly improved the c-statistics for all the genomic markers.
###end p 61
###begin p 62
###xml 0 58 0 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Association of elevated CEP markers with AMD risk genotype</italic>
Association of elevated CEP markers with AMD risk genotype
###end p 62
###begin p 63
###xml 160 161 156 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 219 220 215 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 383 384 379 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Odds ratios were determined for elevated levels of both CEP markers relative to median AMD levels (>/=33 pmol/ml CEP adducts and >/=1.6 CEP autoantibody titer, n = 916 AMD plasma samples). The statistical significance (p values) of differences in CEP marker concentrations between homozygous risk and non-risk donors was determined by the Fisher exact test. Odds ratios, 95% CI, and p values are based on log-transformed CEP marker concentrations.
###end p 63
###begin p 64
###xml 0 39 0 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Characteristics of the study population</italic>
Characteristics of the study population
###end p 64
###begin p 65
###xml 132 138 126 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4</xref>
An additional 98 young control donors (mean age +/- S.D., 42 +/- 6 years; range, 27-50 years) are included in the category </=50 in Fig. 4. Values in parentheses reflect percent of total cohort.
###end p 65

